NAMS
NewAmsterdam Pharma Company N.V.
$35.44
-0.30
(-0.84%)
Mkt Cap
4.14B
Volume
565,191
52W Range
16.785-42.205
Sector
Healthcare
Beta
0.03
EPS (TTM)
-1.81
P/E Ratio
-19.69
Revenue (TTM)
22.57M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 22.50M | 45.56M | 14.09M | 102.69M | 0 | 0 |
| Net Income | (203.82M) | (241.60M) | (176.94M) | (22.63M) | (41.78M) | (7.02M) |
| EPS | -1.75 | -2.56 | -2.15 | -1.19 | -3.34 | -1.15 |
| Free Cash Flow | (148.03M) | (159.24M) | (141.24M) | 10.44M | (29.54M) | (7.36M) |
| FCF / Share | -1.29 | -1.69 | -1.72 | 0.55 | -1.66 | -0.41 |
| Operating CF | (147.78M) | (158.56M) | (141.22M) | 10.66M | (29.51M) | (7.34M) |
| Total Assets | 769.28M | 864.62M | 347.10M | 478.50M | 67.99M | 139.87M |
| Total Debt | 202,000 | 448,000 | 60,000 | 126,000 | 186,511 | 0 |
| Cash & Equiv | 490.00M | 771.74M | 340.45M | 467.73M | 60.38M | 1.37M |
| Book Value | 683.43M | 757.50M | 288.39M | 430.07M | 56.63M | 127.46M |
| Return on Equity | -0.30 | -0.32 | -0.61 | -0.05 | -0.74 | -0.06 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.04M | 32,000 | 348,000 | 19.14M | 2.98M | 12.77M | 29.11M | 2.28M | 1.40M | 803,000 | 2.94M | 1.72M |
| Net Income | (48.44M) | (74.92M) | (72.00M) | (17.36M) | (39.53M) | (92.18M) | (16.65M) | (39.01M) | (93.77M) | (49.49M) | (47.13M) | (38.29M) |
| EPS | -0.40 | -0.65 | -0.61 | -0.15 | -0.34 | -0.98 | -0.18 | -0.41 | -1.06 | -0.52 | -0.56 | -0.43 |
| Free Cash Flow | (30.64M) | (40.98M) | (32.81M) | (37.76M) | (36.48M) | (37.48M) | (12.58M) | (54.19M) | (54.99M) | (33.08M) | (35.33M) | (29.31M) |
| FCF / Share | -0.25 | -0.36 | -0.28 | -0.34 | -0.31 | -0.39 | -0.13 | -0.57 | -0.67 | -0.40 | -0.43 | -0.36 |
| Operating CF | (30.60M) | (40.88M) | (32.77M) | (37.67M) | (36.47M) | (37.48M) | (12.50M) | (53.98M) | (54.60M) | (33.07M) | (35.32M) | (29.30M) |
| Total Assets | 732.64M | 769.28M | 786.43M | 815.11M | 818.41M | 864.62M | 439.19M | 446.69M | 488.46M | 347.10M | N/A | 514.30M |
| Total Debt | 23,000 | 202,000 | 266,000 | 328,000 | 389,000 | 448,000 | 506,000 | 562,000 | 43,000 | 60,000 | N/A | 94,978 |
| Cash & Equiv | 457.61M | 490.00M | 538.41M | 563.86M | 748.42M | 771.74M | 422.73M | 430.71M | 481.15M | 340.45M | N/A | 418.66M |
| Book Value | 665.22M | 683.43M | 728.07M | 778.50M | 777.36M | 757.50M | 378.86M | 387.44M | 411.80M | 288.39M | N/A | 460.99M |
| Return on Equity | -0.07 | -0.11 | -0.10 | -0.02 | -0.05 | -0.12 | -0.04 | -0.10 | -0.23 | -0.17 | N/A | -0.08 |
NAMS News
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial Transcript
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference
Financial Comparison: NewAmsterdam Pharma (NASDAQ:NAMS) and Shineco (NASDAQ:SISI)